Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with Innovent Biologics, Inc. for Fully Human Monoclonal Antibody Drug Discovery
Harbour BioMed announced today that it has licensed its patented H2L2 transgenic mouse platform for generating fully human therapeutic monoclonal antibodies, to Innovent Biologics, Inc., a leading biopharmaceutical company in China. The license was issued through Harbour BioMed’s wholly owned subsidiary, Harbour Antibodies BV.
Harbour BioMed’s transgenic H2L2 platform enables biotechnology and pharmaceutical companies and academic research labs to accelerate new drug development by generating fully human antibodies. Under the licensing agreement, Innovent Biologics has rights to use the H2L2 platform for multiple projects over a multi-year licensing term. Harbour will receive an upfront payment, fees and milestones as well as royalties based on net sales. Specific financial details were not disclosed.
“Innovent joins more than 30 companies and academic institutions globally as licensees to our transgenic mouse platforms for antibody discovery,” said Dr. Jingsong Wang, CEO of Harbour BioMed. “The increasing adoption of our platforms reflects their power as rapid and efficient antibody discovery tools and our strong intellectual property position.” Dr. Wang noted that the transgenic mice platform licensing operations at Harbour Antibodies complements Harbour BioMed’s therapeutic discovery and development business.
About Harbour BioMed
Harbour BioMed is a global
biopharmaceutical company discovering and developing innovative
therapeutics for cancer, with a focus on immuno-oncology, and
immunological diseases. The company's discovery and development programs
are built around its two patented transgenic mouse platforms (Harbour
Mice) for human antibody discovery. The company is building its
proprietary pipeline through its innovative internal discovery programs,
and through in-licensing clinical stage assets that strategically fit
its internal portfolio. Harbour BioMed also licenses the platforms to
companies and academic institutions through its Harbour Antibodies
subsidiary. For additional information, please visit http://www.harbourbiomed.com.
About Harbour Mice
A fully owned subsidiary of Harbour
BioMed, Harbour Antibodies owns two strains of transgenic mice for
generating human therapeutic antibodies: (1) mice that generate
antibodies comprised of two heavy chains and two light chains (H2L2)
with fully human variable regions; and (2) mice that generate novel
“heavy chain only” antibodies (HCAb). The HCAb mice enable the
development of antibody fragment-based therapeutics such as nanobodies,
bi-specific antibodies and CAR-T with favorable drug-like properties.
For additional information, please visit http://harbourantibodies.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171011006129/en/
Timothy Miller
Harbour Antibodies
90 Bridge Street, Suite 100
Newton,
MA 02478, USA
timothy.miller@harbourbiomed.com
